VULVOVAGINAL CANDIDIASIS PREVALENCE AMONG PREGNANT WOMEN IN DIFFERENT HOSPITALS IN IBB, YEMEN by Edrees, Wadhah Hassan et al.
Edrees et al.                                                                    Universal Journal of Pharmaceutical Research 2020; 5(4):1-5                                                   
   
ISSN: 2456-8058                                                                   1                                                   CODEN (USA): UJPRA3    
Available online on 15.9.2020 at http://ujpr.org 
Universal Journal of Pharmaceutical Research  
               An International Peer Reviewed Journal 
                      Open access to Pharmaceutical research 
This is an open access article distributed under the terms of the Creative Commons 
Attribution-Non Commercial Share Alike 4.0 License  which permits unrestricted non 
commercial use, provided the original work is properly cited 
     Volume 5, Issue 4, 2020 
 
RESEARCH ARTICLE                                                  
 
VULVOVAGINAL CANDIDIASIS PREVALENCE AMONG PREGNANT 
WOMEN IN DIFFERENT HOSPITALS IN IBB, YEMEN 
Wadhah Hassan Edrees
1,2
* , Amin Abdo Al-Asbahi
3
, Wadee Abdullah Al-Shehari
4
,  
Eglal Ahmed Qasem
4
 
1Medical Laboratory Department, Faculty of Medical Sciences, Al-Razi University, Yemen. 
2Medical Microbiology Department, Faculty of Applied Sciences, Hajjah University, Yemen. 
3Medical Laboratory Department, Faculty of Medicine and Health Sciences, Amran University. 
4Department of Microbiology, Faculty of Medical Sciences, Ibb University, Yemen. 
 
ABSTRACT
  
Background and aims: Candida species are opportunistic yeasts that affect the genital urinary tract that causes vulvovaginal 
candidiasis in the most females, particularly in developing countries. This work aims to find the prevalence of vulvovaginal 
candidiasis among pregnant women in Ibb, Yemen.  
Material and methods: Two hundred and eighteen samples of females attending outpatient obstetrics and gynecology clinics were 
chosen from several hospitals (Al-Thawra, Maternity and Childhood Center, Maternal Reproductive Health Center, and Nasser 
General Hospital) located in Ibb, from December 2019 to March 2020. The laboratory works were performed in the microbiology 
department of Al-Thawra Hospital, Ibb. Vaginal swabs were cultivated on Sabouraud dextrose agar, then the species of Candida 
identification and anti-fungal sensitivity tests were performed regarding the standard procedure of microbiology.  
Results: The findings revealed that out of 218 cases, 134 (61.5%) were infected with Candida species, and the rate of candidiasis 
was higher among women coming from rural areas than among women in urban areas; and in the age group 28-37 years. C. 
albicans (61.2%) were the most prevalent species followed by C. tropicalis (21.64%), C. glabrata (11.19%), and C. kefyr (5.97%). 
Susceptibility tests showed that the most isolated Candida species were sensitive to nystatin (94.8), fluconazole (91.04%), 
amphotericin B (88.80%), voriconazole (78.35%), clotrimazole (75.37%), ketoconazole (73.13%), and itraconazole (69.40%). 
Conclusion: It can be concluded that Candida vaginitis is very common among pregnant women, and the tested anti-fungal agents 
continue to be effective against all isolates of Candida species. In contrast, there was a slight increase resistant against 
itraconazole, ketoconazole, clotrimazole, and voriconazole which raises concern about a rise in Candida species that are resistant 
to these drugs. 
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INTRODUCTION 
Candida vaginitis, also often called vulvovaginal 
candidiasis, is a pathogen of the vagina caused by 
diverse types of Candida species
1,2
. Vulvovaginal 
candidiasis (VVC) considers the second disease cause 
of symptomatic vaginal diseases after bacterial 
vaginitis
1,3 
and responsible for over 25% of infectious 
vaginitis
4,5
. Almost 75% of women have VVC in their 
lifetime 
3
. Also, it was documented that more than 40% 
of affected females will have two or more incidence of 
vulvovaginal candidiasis in the year
6,7
. The clinical 
manifestations of vulvovaginal candidiasis are 
representing on the itching, vaginal discomfort, an 
unpleasant burning feeling, and soreness that lead to 
whitish-yellowish vaginal discharge often with a curd-
like appearance
8
. The frequency rates of Candida 
species among pregnant women with VVC various 
from the study area to another
9
. Some reports have 
documented that the C. albicans was ranged between 
80-90% among women with acute VVC that caused by 
Candida sp., whereas other species of Candida are less 
frequently isolated
1,10,11
.  However, in the last 10 years, 
there are different species of non-albicans Candida that 
are C. parapsilosis, C. glabrata, C. krusei, C. 
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lusitaniae, C. tropicalis, C. dubliniensis, and C. 
guilliermondii isolated from vaginal samples
12,13,14
. 
Misuse of antifungal drugs and lack of effective 
policies that control the use of antifungal, especially 
against the vulvovaginal candidiasis lead to increase 
resistance of Candida species to several antifungal 
drugs
15
. There are limited reports that documented the 
prevalence of vaginitis in Yemen. A study by AL-Haik 
and Al-Haddad
16
 reported that 39.2% of pregnant 
women have been infected with bacterial vaginosis in 
Hadhramout city. While there have been several 
studies that discussed oral candidiasis in Yemen in the 
past five years
17,18,19
. 
A study, in Sana’a, by Abdul-Aziz et al.,
20  
found that 
the frequency of vaginal infection among reproductive-
aged women was 37.6% of collecting samples. Also, 
the results showed that 27.2% by bacterial vaginosis, 
6.6% by vulvovaginal candidiasis, and 0.9% by 
trichomonal vaginosis. To date, data on the prevalence 
of vulvovaginal candidiasis among women during 
pregnancy period and the rate of resistance to anti-
fungal drugs for Candida species are not available for 
the city of Ibb, Yemen. So, the present study aimed to 
find the prevalence and types of Candida that cause 
vulvovaginal candidiasis among pregnant women and 
their sensitivity to antifungal drugs in Ibb, Yemen. 
 
MATERIALS AND METHODS 
Study Design and Data Collection 
Two hundred and eighteen (218) samples were 
sampled from pregnant women presenting Obstetrics 
and Gynecology outpatient clinics in several hospitals 
(AL-Thwrah, Maternity Center and Childhood, 
Reproductive Health Center for Mothers, Nasser 
General hospital) that situated in Ibb City, in the period 
from December 2019 to March 2020. All participated 
cases were interviewed and patient information was 
reported with intended questionnaires that include; 
demographic, age, medical history, and symptoms.  
Sample Collection 
The swab specimens were collected from female 
pregnant by the obstetrician. By using s sterile cotton 
swab, two wipes per patient, was carefully inserted into 
the upper part of the vagina. The samples were 
immediately transmitted to the diagnostic laboratory of 
the Microbiology Department of the AL-Thwrah 
Hospital for examination
3,21
. 
Examination of Specimen 
Microscopic Examination 
One swab of each case was subjected to direct 
examination by the wet mount. One drop of normal 
saline was transferred to each sample and mixed well 
and microscopically examined under 10x and 40x
22
. 
Culture Methods 
The second swab was cultivated on the surface of 
Sabouraud Dextrose Agar (SDA) (Oxide, UK) with 
chloramphenicol (250mg/l). The plates were incubated 
for 48 h at 37°C. The morphological features for the 
colony were studied and confirmed by detecting the 
budding characterization with pseudo-hyphae by using 
the Gram tube test
23
. 
 
 
Candida species Identification
  
The Candida species were identified according to 
morphological characterizations on the surface of 
culture medium, the formation of germ tube test, and 
carbohydrate assimilation as the following: 
Germ Tube Test 
A small part from a pure colony of Candida species 
was picked and transported into a sterile tube that 
contains 0.5ml serum of human, mixed well, and 
aerobic incubated for 2h at 37°C. Then, one drop of 
each serum was transported to a clean slide and 
scanned by a microscope with objective lenses (x40) to 
identify the existence of germ tubes that characterized 
with initially short hyphal
24
. 
Sugar Assimilation Test 
From the overnight of yeast suspension culture, one 
mL was transferred to the basal carbohydrate-free 
medium (II) of molten agar cooled to 45°C and poured 
to petri dish plates. Saturated discs with 1% with sugar 
were placed on the solidified surface of plates and 
incubated for five days at 37°C. The occurrence of 
growth around each disc implies the carbohydrate 
assimilation of tested sugar. The glucose, sucrose, D-
galactose, maltose, raffinose, lactose, trehalose, and 
xylose were used in the sugar assimilation test
25
. 
Antifungal Susceptibility Testing 
The isolated Candida species were subjected to 
susceptibility antifungal agents by using a disc 
diffusion technique on the surface of Mueller Hinton 
agar. The used antifungal discs were Nystatin (100µg), 
Clotrimazole (50µg), Itraconazole (50µg), Ketocona-
zole (10mg), Voriconazole  (l0µg), Amphoteracin B 
(50µg), and Fluconazole (100µg) (Himedia, India). The 
inhibition zone was measured after 48h of incubation at 
37°C
26
. 
 
RESULTS 
A hundred and thirty-four samples (61.5%) found 
positive growth in culture and 84 specimens (38.5%) 
recorded negative growth (Figure 1). Table 1 shows the 
prevalence of vulvovaginal candidiasis regarding 
patient’s residents. It was observed that the women 
coming from the rural area had the highest rate (65%) 
while the patients coming from the urban area was 
60.13%.  
 
Figure 1: The type of growth in culture media 
 
However, this work revealed that the highest rate of 
infection for first-time was 96/165 (58.18%), while the 
recurrent infection was 38/53 (71.69%). Table 2 shows 
that the highest prevalence of Candida infection was 
73(54.48%) recorded in the group aged 28-37 years 
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and followed by a group aged between 38-47 years 49 
(36.57%). While the lower rate of Candida infection 
was reported in the age group of 18-27 years 
12(8.95%).  
Table 1: Rate of candidiasis infection regard to 
resident 
Residence 
area 
No. of 
examined 
Positive 
(%) 
Negative 
(%) 
Urban 158 95 (60.13) 63(39.87) 
Rural 60 39 (65) 21(35) 
Total 218 134(61.5) 84 (38.5) 
 
The current study found that 96 (71.64%) of cases were 
reported as the first time infected with vulvovaginal 
candidiasis, while 38 (28.36%) of cases were recorded 
as the recurrent vulvovaginal candidiasis (Figure 2).  
 
Figure 2: The first time and recurrent infection 
 
In the present investigation, it was isolated four species 
of Candida from vaginal specimens and identified 
according to carbohydrate assimilation. C. albicans 
was (61.2%) the most predominant Candida species 
identified from specimens followed by an non-albicans 
species that are C. tropicalis 29(21.64%), C. glabrata  
15(11.19%), and C. kefyr 8(5.97%) (Figure 3).  
 
Figure 3: Distribution of isolated Candida species 
from pregnant  
 
Table 2: Prevalence of vulvovaginal candidiasis 
related to age 
Age in 
years 
Examined 
No. (%) 
Positive Candida 
 sp. No. (%) 
18-27 35(16.1) 12 (8.95) 
28-37 122(55.96) 73 (54.48) 
38-47 61(27.98) 49 (36.57) 
Total 218 (100) 134 (100) 
 
The susceptibility results revealed that 94.8% of 
identified Candida species were sensitive to nystatin. 
Fluconazole was the second drug with 91.04% 
susceptible followed by amphotericin B (88.8%), 
voriconazole (78.35%), clotrimazole 75.37%, 
ketoconazole 73.13%, and itraconazole 69.40%. 
Slightly resistance of antifungals was itraconazole, 
ketoconazole, clotrimazole, and voriconazole as shown 
in Table 3.  
Table 3: Antifungal sensitivity profile of isolated 
Candida sp. 
Antifungals Sensitivity 
(%) 
Resistance 
(%) 
Nystatin 127 (94.8) 7(5.2) 
Fluconazole 122 (91.04) 12(8.96) 
Amphoteracin B 119(88.8) 15(11.2) 
Voriconazole 105(78.35) 29(21.65) 
Clotrimazole 101(75.37) 33(24.63) 
Ketoconazole 98(73.13) 36(21.87) 
Itraconazole 93(69.40) 41(29.60) 
 
DISCUSSION 
Vulvovaginal candidiasis represents one of the most 
frequent gynecological disorders caused by an 
overgrowth of Candida species in the mucosa 
membrane of the genital tract in the female
14,27
. In 
present results revealed that 62.5% of specimens were 
positive for Candida sp. growth in culture media while 
38.5% of specimens were negative growth. The 
negative growth could be referred to as an infection 
caused by Trichmonasis vaginitis or bacteria vaginitis. 
In Sana’a, Yemen, Abdul-Aziz et al.,
18
 revealed that 
37.6% was positive for vaginal infections among 
reproductive-age women. Also, Al-mamari et al.,
28
 in 
Sana’a, reported that 94% of vaginal samples of 
patients were positive growth for vulvovaginal 
candidiasis. In the current study, the women coming 
from rural areas had a higher rate (65%) of vaginitis 
than patients from the urban area. This finding in 
disagreement with Abdul-Aziz et al.,
20
 who revealed 
that 88.44% of vaginitis was among reproductive-
women residents in an urban area. The high occurrence 
of communicable vaginitis among rural women 
frequently refers to poor situations of healthcare, 
absence of health education, lower-income, and 
difficulty in medical treatment in time
29
. However, the 
education status plays a significant role in contributing 
to the improvement of personal hygiene which lacks in 
the rural area and that may explain the variance in the 
frequency of infection between the urban area and rural 
area
14
. The results regarding age group showed that the 
higher rate of Candida species infection was most 
frequently noticed among the age of 28-37 years and 
this finding was similar to a study by Al-Karim et al.,
30
 
in Syria. A similar study in Ethiopia by Bitew and 
Abebaw
14
 recorded that the highest rate of vulvo-
vaginal candidiasis was among age groups of 22-44 
years. The current study found that 96 (71.64%) of 
cases were reported as the first time infected with 
vulvovaginal candidiasis, while 38 (28.36%) of cases 
were recorded as the recurrent vulvovaginal 
candidiasis. Most cases in the present work didn’t have 
immunological diseases, so the first time exposure was 
highest and this finding was consistent with Sobel,
31
 in 
Nigeria. C. albicans is normal in a small amount that 
lives in the mucous membranes lining the genitals. It is 
the most responsible for vaginal candidiasis infection 
when occur disrupted in a healthy balance of  
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microorganisms through pregnancy or medication. The 
high level of estrogen in the body during pregnancy 
can upset the healthy balance of microorganisms and 
increase the likelihood of developing a vaginal 
infection by Candida species. Also, various 
medications such as steroids, antibiotics, hormone 
therapy, chemotherapy, and radiotherapy can increase 
the risk too. Additional factors, such as stress, genitals 
washing with soap, wearing synthetic and tight clothes, 
sweating and using panty liners or sanitary pads. The 
present investigation reported that the C. albicans was 
the most isolated of Candida species with 61.2% from 
pregnant women suffering from vaginal candidiasis 
symptoms and this result is consistent with the report 
of Al-mamari et al.,
28 
who found that the 65.95% of 
isolated Candida species was C. albicans. Another 
study by Omar et al.,
35
 in Egypt showed that C. 
albicans was the highest (78.3%) isolated species from 
infected women by vaginitis. In the last three decades, 
it has been observed that there was an increase in the 
percentage of vaginitis caused by species of Candida 
non-albicans. The present work revealed an increase in 
the frequency of non-albicans species considers as 
potential causes of vulvovaginal candidiasis. It was 
found that C. tropicalis (1.64%), C. glabrata (11.19%), 
and C. Kefyr (5.97%) were recorded in this study. This 
finding was supported by a similar study by Babin et 
al.,
34 
in Iran. The results of antifungal susceptibility, it 
was reported that all isolates were susceptible to tested 
antifungals. The highest sensitivity of antifungals 
against isolated Candida species was nystatin (94.8), 
fluconazole (91.04%), amphotericin B (88.8%), 
voriconazole (78.35%), clotrimazole (75.37%), 
ketoconazole (73.13%), and itraconazole (69.40%). 
Whereas slight resistance of antifungals was 
itraconazole, ketoconazole, clotrimazole, and voricona-
zole as reported against isolated Candida species. 
These findings are in agreement with the work of 
researchers that observed that most isolated Candida 
species were susceptible to tested antifungals
28,35,36,37
. 
 
CONCLUSION 
It can be concluded that vulvovaginal candidiasis is 
very common among pregnant women, and the tested 
anti-fungal agents continue to be effective against all 
isolates of Candida species. In contrast, there was a 
slight increase in resistance against itraconazole, 
ketoconazole, clotrimazole, and voriconazole which 
raises concern about a rise in Candida species that are 
resistant to these drugs. 
 
CONFLICT OF INTEREST  
No conflict of interest associated with this work.  
 
AUTHOR’S CONTRIBUTION 
The manuscript was carried out, written, and approved 
in collaboration with all authors. 
 
REFERENCES 
1. Achkar JM, Fries BC. Candida infections of the 
genitourinary tract. Clin Microbial Rev 2010; 253-273. 
https://doi.org/10.1128/CMR.00076-09 
2. Eiderbrant K. Development of quantitative PCR methods 
for diagnosis of bacterial vaginosis and vaginal yeast 
infection. M.Sc. Thesis, Linkopings University, 
Linkoping, Sweden 2010; 25-114. 
3. Ishida K, Ueda-Yamaguchi M, Yamada-Ogatta S, Ueda-
Nakamura T, Svidizinski T, Nakamura C. 
Characterization of Candida spp. isolated from vaginal 
fluid: Identification, antifungal susceptibility, and 
virulence profile. Acta Scientiarum2013; 35(1): 1-8. 
https://doi.org/10.4025/actascihealthsci.v35i1.13557 
4. Corsello S, Spinillo A, Osnengo G, Pena C, Guaschino S, 
Beltrame A. An epidemiological survey of vulvovaginal 
candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 
2003; 110:66-72.  
https://doi.org/10.1016/s0301-2115(03)00096-4 
5. Grigoriou O, Baka S, Makrakis E, Hassiakos D, 
Kapparos G, Kouskouni E. Prevalence of clinical vaginal 
candidiasis in a University Hospital and possible risk 
factors. Eur J Obstet Gynecol Reprod Biol 2006; 
126(1):121-125. 
https://doi.org/10.1016/j.ejogrb.2005.09.015 
6. Das-Neves J, Pinto E, Teixeira B, Dias G, Rocha P, 
Cunha T. Local treatment of vulvovaginal candidosis: 
General and practical considerations. Drugs 2008; 68 
(13):1787-1802.  
https://doi.org/10.2165/00003495-200868130-00002 
7. Eschenbach DA. Chronic vulvovaginal candidiasis. N 
Engl J Med 2004; 351:851-852.  
https://doi.org/10.1056/NEJMp048152 
8. Morreira D, Paula CR. Vulvovaginal candidiasis. Int J 
Gynaecol Obstet 2006; 92: 266-267. 
https://doi.org/10.1016/j.ijgo.2005.12.007 
9. Deoruhkar SC, Saini S. Vulvovaginal candidiasis due to 
non-albicans Candida: Its species distribution and 
antifungal susceptibility profile. Int J Curr Microbial App 
Sci 2013; 2(12): 323- 328.  
10. Ben-Haroush A, Yogev Y, Kaplan B. The importance of 
diagnostic work-up in the management of candidal 
vulvovaginitis: a prospective study. Clin Exp Ob stet 
Gynecol 2004; 31:113- 116. PMID: 15266763 
11. Boselli F, Chiossi G, Garutti P, Matteelli A, Montagna 
MT, Spinillo A. Preliminary results of the Italian 
epidemiological study on vulvovaginitis. Minerva 
Ginecol 2004; 56:149-153. PMID: 15258544 
12. Babic M, Dukie M. Candida albicans and non-albicans 
species as etiological agent of vaginitis in pregnant and 
non-pregnant women. Bosn J Basic Med Sci 2010; 10 
(1):89-97. https://doi.org/10.17305/bjbms.2010.2744 
13. Ameri S, Falahati M, Kordbache P, Zaini F, Rahimi P. 
Activities of fluconazole in combination with terbinafine 
against non-albicans Candida species isolated from the 
patients with recurrent vulvovaginal candidiasis in 
comparison with ciclopirox olamine. Hormozgan Med J 
2015; 18 (6): 516-521. 
14. Bitew A, Abebaw Y. Vulvovaginal candidiasis: species 
distribution of Candida and their antifungal susceptibility 
pattern. BMC Women's Health 2018; 18:94. 
https://doi.org/10.1186/s12905-018-0607-z  
15. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema 
DJ, Pfaller MA. Antifungal susceptibilities of Candida 
species causing vulvovaginitis and epidemiology of 
recurrent cases. J Clin Microbiol 2005; 43, 2155-2162. 
https://doi.org/10.1128/JCM.43.5.2155-2162.2005 
16. AL-Haik WM, Al-Haddad AM. Bacterial vaginosis 
among pregnant women in Hadhramout-Yemen. 
Alandalus J Appl Sci 2017; 7(16):23-33. 
17. Al-Kebsi AM, Othman AM, Al-Kasem MAA, Madar 
EM, Al-Shamahy HA, Al-Gaffari KM, Daname SMN, 
Motareb FL. Oral C. albicans colonization and non-
candida albicans candida colonization among University 
students, Yemen. Universal J Pharm Res 2017; 2(5): 5-9. 
http://doi.org/10.22270/ujpr.v2i5.R2  
18. Shoga Al-deen HM, Ahmed Ali  O, Al-Shamahy HA, 
Al-Shami IZ, Saleh AL-amri MA, Al-labani MAC 
Edrees et al.                                                                    Universal Journal of Pharmaceutical Research 2020; 5(4):1-5                                                   
   
ISSN: 2456-8058                                                                   5                                                   CODEN (USA): UJPRA3    
(2020) Oral Candida albicans colonization rate in fixed 
orthodontics patients. Universal J Pharm Res 2020; 
5(2):1-5. https://doi.org/10.22270/ujpr.v5i2.380    
19. Al-Haddad KA, Al-dossary OAE, Al-Shamahy HA. 
Prevalence and associated factors of oral non-Candida 
albicans Candida carriage in denture wearers in Sana’a 
city-Yemen. Universal J Pharm Res 2018; 3(4): 7-11. 
https://doi.org/10.22270/ujpr.v3i4.176  
20. Maha AA, Mahdy AK, Ghani RA, et al. Bacterial 
vaginosis, vulvovaginal candidiasis and trichomonal 
vaginitis among reproductive-aged women seeking 
primary healthcare in Sana’a city, Yemen. BMC 
Infectious Diseases. 2019; 19:879-889.  
https://doi.org/10.1186/s12879-019-4549-3 
21. Narkwa W. Antifungal susceptibility of Candida species 
and Cryptococcus neoformans isolated from patients at 
the Komfo Anokye Teaching Hospital in Kwnasi. M.Sc. 
Thesis, Kwame Nkrumah University of Science and 
Technology, Kumasi, Ghana. 2010. 
22. Lennox JA, Abbey SD, Udiba D, Mboto CI, Ikpoh IS, 
Akubuenyi FC. Prevalence of vaginitis and vaginosis 
among University of Calabar female students. J Public 
Health Epid 2013; 5(4): 167-172. 
23. Rohde B, Hartmann G, Haude D, Kessieler HG, Langen 
ML. Introducing mycology by examples. Presented by 
Schering Aktiengesellschaft. Hamburg 1980; 35-98. 
24. Isibor JO, Eghubare AE, Omoregie R. Germ tube 
formation in Candida albicans. Shiraze Med J 2005; 6 (1 
and 2). 
25. Jayalakshmi L, Kumari GR, Samson SH. Isolation, 
speciation and antifungal susceptibility testing of 
Candida from clinical specimens at a tertiary care 
hospital. J App Med Sci 2014; 2(6):3193-3198. 
26. Clinical and Laboratory Standards Institute (CLSI). 
Performance Standards for Antimicrobial Disk 
Susceptibility Tests; Approved Standard. Twenty-
sixth editions 2016; 58-116. 
27. Rajkumar R, Radhakrishnan S, Seenivasan C, Kannan S. 
Culture and identification of Candida albicans from 
vaginal ulcer and separation of Enolase on SDS -PAGE. 
lnte J Bio 2010; 2(1): 84-93.  
28. Al-mamari A, Al-buryhi M, Al-heggami AM, Al-hag S. 
Identify and sensitivity to antifungal drugs of Candida 
species causing vaginitis isolated from vulvovaginal 
infected patients in Sana’a city. Der Pharma Chemica, 
2014; 6(1):336-342. 
29. Abbas AM, Shaaban OM, Badran SM, Shaltout AS, Nasr 
A, Abdullah SA. Risk factors and health hazards of 
vaginal infections in upper Egypt: A cross sectional 
study. Thai J Obstet Gynecol 2016; 30: 50-6.  
https://doi.org/10.14456/tjog.2016.14 
30. Al-Karim M, Maarouf M, Chahine E. The role of 
personal and medical factors and general state in fungal 
vaginitis in Syrian women. J Damascus Univ Health 
Scien 2007; 23(1): 239-249. 
31. Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369: 
1961-1971.  
https://doi.org/10.1016/S0140-6736(07)60917-9 
32. Ferrer J. Vaginal candidosis: epidemiological and 
etiological factors. Int J Gynecol Obst 2000; 71:S21–
S27.  
https://doi.org/10.1016/s0020-7292(00)00350-7 
33. Grigoriou O, Baka S, Makrakis E, et al. (2006) 
Prevalence of clinical vaginal candidiasis in a university 
hospital and possible risk factors. European J Obst 
Gynecol Reprod Biol 126(1):121-125.  
https://doi.org/10.1016/j.ejogrb.2005.09.015 
34. Babin D, Kotigadde S, Rao P, Rao T. Clinico-
mycological profile of vaginal candidiasis in a Tertiary 
Care Hospital in Kerala. lnt J Res Bio Sci 2013; 3(1):55-
59. 
35. Omar MS, Abbas AM, Moharram AM, Farhan MM, 
Hassanen IH. Does vaginal douching affect the type of 
candidal vulvovaginal infection? Myd Mycol 2015; 
53(8):817-827. https://doi.org/10.1093/mmy/myv042 
36. Abruquah HH. Prevalence and antifungal susceptibility 
of Candida species isolated from women attending 
Gynaecological clinic in Kumasi, Ghana. Ournal Sci 
Tech 2012; 32 (2): 39-45.  
https://doi.org/10.4314/just.v32i2.6 
37. Khan M, Ahmed J, Gul A, Ikram A, Lalan KF. 
Antifungal susceptibility testing of vulvovaginal Candida 
species among women attending antenatal clinic in 
tertiary care hospitals of Peshawar. Infection Drug 
Resist 2018; 11: 447–456.  
http://dx.doi.org/10.2147/IDR.S153116 
 
